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Abstract
Objectives: This study aimed to update and validate a prediction rule for respiratory syncytial virus (RSV) hospitalization in
preterm infants 33–35 weeks gestational age (WGA).
Study Design: The RISK study consisted of 2 multicenter prospective birth cohorts in 41 hospitals. Risk factors were assessed
at birth among healthy preterm infants 33–35 WGA. All hospitalizations for respiratory tract infection were screened for
proven RSV infection by immunofluorescence or polymerase chain reaction. Multivariate logistic regression analysis was
used to update an existing prediction model in the derivation cohort (n = 1,227). In the validation cohort (n = 1,194),
predicted versus actual RSV hospitalization rates were compared to determine validity of the model.
Results: RSV hospitalization risk in both cohorts was comparable (5.7% versus 4.9%). In the derivation cohort, a prediction
rule to determine probability of RSV hospitalization was developed using 4 predictors: family atopy (OR 1.9; 95%CI, 1.1–3.2),
birth period (OR 2.6; 1.6–4.2), breastfeeding (OR 1.7; 1.0–2.7) and siblings or daycare attendance (OR 4.7; 1.7–13.1). The
model showed good discrimination (c-statistic 0.703; 0.64–0.76, 0.702 after bootstrapping). External validation showed good
discrimination and calibration (c-statistic 0.678; 0.61–0.74).
Conclusions: Our prospectively validated prediction rule identifies infants at increased RSV hospitalization risk, who may
benefit from targeted preventive interventions. This prediction rule can facilitate country-specific, cost-effective use of RSV
prophylaxis in late preterm infants.
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Introduction
Respiratory syncytial virus (RSV) bronchiolitis is one of the
most common causes of infant hospitalization during the winter
season and is associated with a large burden of disease and high
costs.[1–5] Hospitalization for RSV lower respiratory tract
infection in Europe and the United States is estimated to be 1–
3% of all infants aged less than 13 months. Important risk groups
for RSV bronchiolitis are infants with prematurity with or without
chronic lung disease, congenital heart disease, Down syndrome
and immunodeficiencies.[6–9] Although risk groups for RSV
bronchiolitis have been identified, the precise incidence of
hospitalization for RSV bronchiolitis in these patient populations
is generally not known. There is no effective therapy for RSV
infection, so treatment is mainly symptomatic.[10] Due to the
increased risk most high risk groups receive RSV immunopro-
phylaxis to prevent RSV infection. Palivizumab, a humanized
immunoglobin monoclonal antibody, specific for RSV, has been
proven effective and safe for preterm infants with gestational age
#35 weeks, infants with bronchopulmonary dysplasia and infants
with congenital heart disease.[11,12] Efficacy of 55% of RSV
prophylaxis has been demonstrated for late preterm infants 33–35
weeks gestational age (WGA). Subgroup analysis showed 80%
efficacy of RSV prophylaxis in 32–35 WGA preterm infants.[12]
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In many countries RSV immunoprophylaxis is not used in late
preterm infants 33–35 WGA because of high costs.[13] Within
health care, limited budgets force the need to selectively apply high
cost treatments to a proportion of infants identified as having
increased risk for severe disease. Costs may be reduced by
targeting RSV immunoprophylaxis to 33–35 WGA late preterm
infants with additional risk factors.[14] Several environmental and
clinical risk factors have been described which compound the risk
for severe RSV disease. Presence of siblings, daycare attendance,
month of birth and protective factors like breastfeeding have been
described as independent risk factors for severe disease due to
RSV infection.[15–21] In a recent paper it was emphasized that
validated prediction rules are required to improve the care of our
patients with infectious diseases.[22] Two prediction rules for late
preterm infants 33–35 WGA have been published but these have
not yet been validated prospectively.[23,24] To develop a practical
and accurate prediction model for the Netherlands the prediction
rule previously developed by Simoes et al. may have inferior
performance in countries, such as the Netherlands, in which most
children visit day care facilities.[24] We therefore aimed to update
and validate a RSV prediction rule for 33–35 WGA late preterm
infants using 2 prospective birth cohorts.[24]
Methods
Study design
RISK is an ongoing study prospectively performed in late
preterm infants born at 32 weeks and 1 day to 35 weeks and 6 days
weeks gestational age (referred to as 33–35 WGA) in 41 hospitals
of the RSV Neonatal Network in the Netherlands. Between June
2008 and January 2011 infants were included in hospitals located
across the Netherlands. The study population consisted of
newborn infants born at 33–35 WGA from 1 university hospital
and 40 regional hospitals. Infants with gross abnormalities or
Down syndrome, and those who received palivizumab for any
reason were excluded. The study consists of 2 subsequent birth
cohorts: a derivation cohort and a validation cohort.
Ethics statement
The study was reviewed and approved by the Institutional
Review Board of the University Medical Center Utrecht and
subsequently approved by Institutional Review Boards of all
participating hospitals. All parents provided written informed
consent for screening of hospital records. The study was conducted
in compliance with the Declaration of Helsinki and the standards
of Good Clinical Practice.
Data collection
At birth, a questionnaire containing questions on family history
of wheeze, asthma and hay fever, smoking during pregnancy and
in the household, the number of siblings and their age, parental
education level, potential breastfeeding, potential day-care atten-
dance, household pets and pregnancy details was filled out by
parents. Clinical data on the mode of delivery, gestational age,
respiratory support, birth weight, Apgar score and delivery details
were derived from patient charts. The following 7 variables from
the prediction rule previously developed by Simoes et al. were
noted: ‘birth within 10 weeks of the start of the season,’ ‘birth
weight,’ ‘breast-feeding #2 months,’ ‘number of siblings $2 years
of age,’ ‘number of family members with atopy,’ ‘male sex,’ and
‘number of family members with wheeze’[24]. Breast-feeding was
defined as either exclusive breastfeeding or mixed with formula
feeding. Atopy was defined as the presence of asthma, eczema or
hay fever. At one year of age, parents were contacted by telephone
to determine whether hospitalization for respiratory disease had
occurred. If any data were missing from questionnaires completed
by the parents/legal guardians or from the clinical records, the
respective physician was contacted for information, which ensured
that all baseline data were assembled. If the parents could not be
reached by telephone, the hospital and general practitioner were
contacted for updated information. If no valid telephone number
was available, an e-mail or letter was sent to the parents.
Outcome definition
When parents reported hospitalization for respiratory disease
during the first year of life, we analysed the medical hospital record
for RSV hospitalization, including routine virology results. The
main study endpoint, hospitalization for RSV bronchiolitis was
defined as hospitalization for lower respiratory tract infection with
proven RSV infection determined by routine practice laboratory
testing in the participating hospitals, i.e. either by rapid RSV
immunofluorescence test or polymerase chain reaction.
Statistical analysis
Sample size calculation: According to a generally accepted rule
of thumb that at least 10 cases are required per variable in the
prediction rule. For a 7-variable model we calculated a priori, a
sample size of 70 infants hospitalized for RSV bronchiolitis.[24]
With an estimated incidence of 4%, the projected sample size of
the derivation cohort was 1,750. To validate a 4-variable
prediction rule, the estimated sample size of the validation cohort
was 1,000.
Derivation and validation of the prediction rule
We assessed the test performance of the clinical prediction rule
to identify infants at high risk for hospitalization with RSV
bronchiolitis. To evaluate the models’ calibration, the Hosmer-
Lemeshow statistic was used in which observations are grouped
based on deciles of predicted probability and compared with the
observed risk of RSV bronchiolitis in the derivation and validation
cohort. This was graphically assessed with a calibration plot and
tested with the Hosmer-Lemeshow statistic, where a non-
significant test indicated good model fit.[25,26] Discrimination is
the ability of the rule to distinguish between infants hospitalized
from those not hospitalized for RSV bronchiolitis, and will be
quantified with the Area Under the Receiver Operating Charac-
teristic curve (AUROC). An AUROC area ranges from 0.5 (no
discrimination.) to 1.0 (perfect discrimination).
We anticipated that the prediction rule previously developed by
Simoes et al. may have inferior performance in countries, such as
the Netherlands, in which most children visit day care facilities.
Therefore we planned to update the model. Multivariable logistic
regression was used to update the independent contribution of
each of the variables to the discrimination of the model. The
updated model was reduced by excluding variables from the
model with univariate p-values .0.15, using the log likelihood
ratio test. The AUROC was used to determine whether the
variables provided added predictive value beyond the existent
prediction rule.[27] Other, additional variables with a univariate
p-value of ,0.15 not included in the original prediction rule were
added to increase the discrimination and reliability of the
prediction rule. Subsequently, the model shrinkage was applied
in the derivation dataset using bootstrapping, to adjust the model’s
estimated regression coefficients in order to reduce overfit-
ting.[25,28] We repeated the modelling process in 1,000 bootstrap
samples. For each individual infant the risk score was calculated
using the bootstrap-corrected coefficients of the updated predic-
tion rule. The value of each risk factor was multiplied by its
RSV Bronchiolitis Prediction in Late Preterms
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coefficient and the sum of all resulting values and the model
intercept, i.e. the linear predictor, was calculated. The results of
the validation were examined primarily by classification tables and
by calculating the AUROC. To make the model easy to use in a
clinical setting we calculated a point score.
The updated prediction rule was externally validated in a new
cohort of infants. The two cohorts were derived by making a non-
randomized split according to birth date.[29]
We defined our derivation cohort as all infants born between
June 2008 and September 2009, and our validation cohort as all
infants born between September 2009 and January 2011. We
calculated performance of the rule as sensitivity, specificity,
positive likelihood ratio and negative likelihood ratio. Statistical
analysis was performed by using SPSS 15.0. (SPSS Inc, Chicago,
Ill).
Results
Patient characteristics
In total, 2,703 infants born in the 41 participating hospitals were
included (figure 1, table 1); 186 infants (7%) were lost to follow-up
after a year. Three infants died of RSV-unrelated causes. Of the
2,514 included infants, 198 parents reported hospitalization for
respiratory tract symptoms during the first year of life and these
were verified through hospital medical records. For these 198
hospitalizations, tests for RSV were positive in 129 instances
(5.1%) and negative in another 41 (1.6%). Testing for RSV was
not performed in 28 cases.
Derivation of the prediction rule
Table 2 shows the distribution of potential predictors of RSV
bronchiolitis. In the derivation cohort we updated a previously
published prediction rule.[24] Of the seven predictors in this
original model the following four variables ‘birth within 10 weeks
of the start of the season,’ ‘breast-feeding #2 months’, ‘number of
siblings $2 years of age’, ‘number of family members with atopy’,
contributed significantly. Updating the model by adjusting the four
original variables to increase discrimination and by stepwise
backward selection in the derivation cohort resulted in the final 4-
variable model including ‘born Aug 14 th to Dec 1 st’, ‘presence of
siblings or day care attendance’, ‘atopy in a 1st degree family
member’ and ‘breast-feeding #2 months’. The AUROC of this
updated model was 0.703 (95% CI 0.64–0.76) before boot-
strapping and 0.702 (0.64–0.76) afterwards (Table 3). We used
point values generated from the five times multiplied and rounded
regression coefficients to develop a score. We entered the scores of
each patient in a logistic regression model to generate the
individual predicted probability of RSV hospitalization. For scores
$16 mean predicted probabilities were 10.0% (95% CI 7.0–
14.2%) versus 3.5% in scores ,16.
Validation of the prediction rule
In our independent validation sample, the updated prediction
rule demonstrated satisfactory discrimination (AUROC, 0.678;
95% CI 0.61–0.74) (Table 3). In the calibration plot, the intercept
was 0.0, the slope was 1.0, indicating good calibration. The
Hosmer-Lemeshow test resulted in a p-value of 0.26, and the
average absolute difference in predicted and calibrated probabil-
ities was 0.008. We calculated sensitivity, specificity and diagnostic
likelihood ratios for each score defined as high-risk categories
(Table 4). Using a threshold score$16 we observed that 27 infants
(positive predictive value 10%) were hospitalized for RSV
bronchiolitis in the validation cohort. We calculated the following
other characteristics of the RISK prediction rule: negative
predictive value of 96%, sensitivity of 46% (95% CI 34–58%), a
specificity of 79% (95% CI 76–81%), a positive likelihood ratio of
2.1 (95% CI 1.6–2.9) and a negative likelihood ratio of 0.7 (95%
CI 0.5–0.9).
Discussion
We showed that the overall RSV hospitalization risk was 5.1%
in this population of healthy late preterm infants 33–35 WGA. As
far as we are aware, this is the first prospective validation study for
RSV hospitalization in late preterm infants. The sample size was
large enough for both updating and validating the updated
prediction rule. The 4-variable prediction rule can be used to
further target preventive interventions at those infants who have
the highest risk for hospitalization caused by RSV infection.
Two previous studies described prediction rules for RSV
hospitalization in late preterm infants.[23,24] The group of
Figueras-Aloy developed a 7-variable prediction rule for RSV
hospitalization in a group of late preterms born between 33–35
weeks of gestation. This model was retrospectively validated in
French, Italian and Danish cohort studies or case-control
studies.[30–33] We updated the Spanish prediction rule aiming
to produce a model which is both valid and practical in clinical
use. The predictors in our prediction rule are also in agreement
with a Canadian prediction model.[31] This model was retro-
spectively validated in the case-control study used to develop the
Spanish prediction rule.[23] Although the Canadian study has not
been prospectively validated, this study is used for targeted
prophylaxis in Canada. The performance of the RISK prediction
model is remarkably similar to the actual impact of the Canadian
model as it targets 22% of the late preterm cohort which is
comparable to the performance of the prediction rule used in
Canada which targets 18% of late preterms of 33–35 WGA.[31]
The major strengths of our study include: that data from 2 large
prospective cohorts were collected allowing further validation of
an existing RSV prediction rule, the retrieval of complete baseline
Figure 1. Patient flowchart derivation and validation cohort.
doi:10.1371/journal.pone.0059161.g001
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data, and palivizumab was used by less than 5% in our study
population because it is not reimbursed. The majority of infants
who received palivizumab in our study population had either a
congenital anomaly or chronic lung disease. Some potential
limitations included the following. First, an underestimation of
RSV hospitalization may have occurred, because not all infants
hospitalized for respiratory tract infections were routinely tested.
Underestimation of the risk of RSV hospitalization is unlikely to
have affected the AUROC of the prediction rule, but would result
in an underestimation of the positive predictive value. Second, of
Table 1. Distribution of Baseline Patient Characteristics in the Derivation and Validation Cohort (Number(percentage)).
Derivation cohort (n =1,227) Validation cohort (n=1,194)
Male gender 676 (55.1%) 659 (55.2%)
Gestational age (wk) 34 34
32 115 (9.4%) 124 (10.4%)
33 296 (24.1%) 240 (20.1%)
34 371 (30.2%) 429 (35.9%)
35 445 (36.3%) 401 (33.6%)
Birth Weight (g) (Mean(SD)) 2214 (452) 2225 (427)
Multiple pregnancy 426 (34.7%) 422 (35.3%)
Caesarean section 409 (33.3%) 436 (36.5%)
Continuous positive airway pressure 166 (13.5%) 217 (18.2%)
Mechanical ventilation* 46 (3.7%) 35 (2.9%)
Born Aug 14 th to Dec 1 st 324 (26.4%) 496 (41.5%)
Breastfeeding** less than 2months or not # 416 (33.9%) 376 (31.5%)
Presence of siblings 504 (41.1%) 463 (38.8%)
Atopy in 1st degree family member 642 (52.3%) 729 (61.1%)
Fur bearing pets 571 (46.5%) 548 (45.9%)
Maternal smoking during pregancy 164 (13.4%) 136 (11.4%)
Subject daycare attendance # 730 (59.5%) 714 (59.8%)
Number of house hold residents (Median (95%CI)) 3 (2–4) 3 (2–4)
Siblings or subject daycare attendance 959 (78.2%) 918 (76.9%)
*No infants developed BPD ** either exclusive breastfeeding or mixed with formula feeding # predicted by parents at birth.
doi:10.1371/journal.pone.0059161.t001
Table 2. Distribution of potential predictors across cases and non-cases in the derivation and validation cohort.
Derivation cohort (n =1,227) Validation cohort (n=1,194)
Characteristic (Number (%)) RSV hospitalization (n =70) Controls (n =1,157) RSV hospitalization (n =59) Controls (n=1,135)
Born Aug 14 th to Dec 1 st 32 (45.7%) 292 (25.2%) 35 (59.3%) 461 (40.6%)
Gestational age (weeks) (Median
(95%CI))
34 (32235) 34 (32235) 34(32235) 34 (32235)
Birth weight, gr (Mean (SD)) 2216 (483) 2214 (450) 2215 (395) 2200 (428)
Breast fed* # 2 months or not# 32 (45.7%) 384 (33.2%) 20 (33.9%) 356 (31.4%)
Presence of siblings 46 (65.7%) 458 (39.6) 33 (55.9%) 430 (37.9%)
Atopy in 1st degree family member 46 (65.7%) 596 (51.5%) 41 (69.5%) 688 (60.6%)
Male gender 39 (55.7%) 637 (55.1%) 29 (49.2%) 630 (55.5%)
Fur bearing pets 27 (38.6%) 544 (47.0%) 22 (37.3%) 526 (46.3%)
Maternal smoking during pregancy 11 (15.7%) 153 (13.2%) 9 (15.3%) 127 (11.2%)
Subject daycare attendance# 47 (67.1%) 683 (59.0%) 41 (70.7%) 673 (59.4%)
Number of residents 3.1 (0.84) 2.8 (0.80) 3.0 (0.80) 3.0 (0.80)
Siblings or subject daycare
attendance
66 (94.3%) 893 (77.2%) 55 (93.2%) 863 (76.0%)
Multiple birth 25 (35.7%) 401 (34.7%) 14 (23.7%) 408 (36.1%)
*either exclusive breastfeeding or mixed with formula feeding # predicted by parents at birth.
doi:10.1371/journal.pone.0059161.t002
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all infants with a score ,16, 3.5% will be hospitalized for RSV
bronchiolitis while not classified as high risk. Third, 6.1% of
parents could not be contacted after 1 year despite attempts to
obtain contact details via the hospital, general practitioner or a
web-based search and this could be a potential selection bias.
Since the vast majority of parents were contacted we believe this
does not significantly jeopardize the conclusions of this study.
Fourth, this study does not answer the on-going question of cost-
effectiveness of RSV immunoprophylaxis in late preterm in-
fants.[13,14,34–39] Conflicting reports on this matter have
recently been published.[36,40–42] However, applying the RISK
prediction rule will certainly improve cost-effectiveness of RSV
prophylaxis. Five, because there is no gold standard for RSV
prediction we were unable to assess the criterion validity of the
RISK prediction model. Content, construct and face validity were
accounted for because our analyses covered all relevant RSV risk
factors and the outcome of our model is based on laboratory
confirmed RSV hospitalizations. Since we externally validated the
prediction model in a prospective and independent second cohort
we believe the model was sufficiently validated.
The RISK prediction model incorporates four simple clinical
variables which combined can be used for risk stratification in the
birth period among late preterm infants. The RISK model
provides an important foundation for targeted prevention for those
infants most at risk for severe RSV disease. With the RISK
prediction rule a high risk group can be identified with a
hospitalization risk .10% which is comparable to the hospital-
ization risk in preterm infants,32 weeks gestational age and other
high risk groups.[6,7] If a risk score of 16 is applied, then infants
with a risk score exceeding this threshold comprise 22% of all
preterm infants 33–35 weeks gestational age. By targeting only
22% of this large birth cohort of late preterm infants for
prophylaxis, the potential impact of our model is not dissimilar
to the Canadian findings.[31] Future research should focus on the
confirmation of the impact of the RISK prediction rule during
implementation in clinical guidelines.
Conclusion
The risk of hospitalization for RSV bronchiolitis in late
preterms is 5.1%. The RISK prediction rule is a simple clinical
rule identifying a subgroup of 33–35 WGA late preterm infants
with increased risk of hospitalization for RSV bronchiolitis.
Implementation of the RISK prediction rule will further improve
cost-effectiveness of RSV prophylaxis.
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